Merck & Co., Inc.
http://www.merck.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck & Co., Inc.
IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
FDA Expedites ANDA Postapproval Manufacturing Changes
Generic drugs program has approved almost 300 manufacturing changes to help shore up the supply chain, with some prior approval supplements being downgraded to ‘changes being effected’ supplements, FDA officials said at GDUFA III kick-off meeting.
US FDA Picks Up The Pace Of Complete Response Letters Over June And July
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abmaxis
- Acacia Biosciences
- Afferent Pharmaceuticals
- ArQule, Inc.
- Avecia Biologics Limited
- Banyu Pharmaceutical Co., Ltd.
- Calporta Therapeutics
- cCAM Biotherapeutics Ltd.
- Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.)
- Idenix Pharmaceuticals, Inc.
- Immune Design Corporation
- Inspire Pharmaceuticals, Inc.
- IOmet Pharma
- iOnctura SA
- Integrated Therapeutics Group
- Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
- MSD K.K. (Japan)
- Nobilon International BV
- Novacardia
- OncoEthix SA
- Organon BioSciences
- Peloton Therapeutics, Inc.
- Rigontec GmbH
- Schering-Plough Corporation
- SmartCells, Inc.
- Tilos Therapeutics, Inc.
- Vallee S.A.
- Viralytics Limited (ASX:VLA)
- Themis Biosciences GmbH